SLEAP Statistical Analysis Plan
Details
Further Details:
Guiding analytic approaches: For this effectiveness trial, all statistical analyses will be based on an intention-to-treat approach. All participants will be analyzed according to the allocated intervention, whether they received it or not.
Baseline analyses: Baseline characteristics of patients in the 2 treatment arms will be assessed using frequency distributions and univariate descriptive statistics including measures of central tendency and dispersion. We will compare all major baseline variables for both arms to identify any clinically meaningful imbalances that may influence the primary outcome.
Principal analysis of primary outcome measure: We will compare the time to the development of our primary outcome (successful extubation) between patients allocated to protocol-directed sedation and daily interruption versus protocol-directed sedation alone. Successful extubation is defined as when a patient is extubated, and remains extubated for >48h. Unadjusted rates of time to extubation with 95% confidence intervals will be compared using log-rank tests. In addition, Cox proportional hazards regression models will be used to determine a crude hazard ratio and to further elucidate the measure of effect while adjusting for possible confounding variables. Censoring of the primary outcome will occur at death, transfer to another institution, or 28 days. We will also conduct a per-protocol analysis of patients who had interruptions on more than 75% of eligible study days, Principal analysis of secondary outcome measures: As with the primary outcome, unadjusted survival rates with 95% confidence intervals will be calculated for ICU, mortality, hospital mortality, ICU discharge, and hospital discharge. Cox proportional hazards regression models will be used to evaluate the measure of effect while adjusting for possible confounding variables. The dichotomous outcomes such as self-removal of Foley catheter, endotracheal, or nasogastric tubes will be analyzed using Chi-square tests for unadjusted proportions. If all assumptions are met for parametric analyses of the continuous variables, we will use a 2-sample t-test; otherwise, we will use a 2-sample Wilcoxon Rank Sum test. Mean SAS and VAS scores per patient, and mean differences with 95% confidence intervals will be calculated.
Subgroup Analyses:
We will conduct one pre-specified subgroup analysis, based on classification of a patient's ICU admission as medical versus surgical/trauma. We hypothesize that medical patients would benefit more than surgical patients from daily interruption, given their anticipated longer durations of mechanical ventilation and sedative infusions. We will apply a treatment by subgroup interaction to assess whether the magnitude of treatment effect is significantly different between subgroups.
SLEAP Determination of Sample Size
Our primary outcome is time-to-extubation. Given that the distribution of mechanical ventilation (MV) days is not normal, we ran simulations based on finding a 2 day difference in median days between the 2 arms. The longer the duration of MV, the greater the risk of complications associated with intubation and immobility. A 2-day difference in median MV days was determined by investigators, experts and CCCTG members at the January 2007 meeting, as clinically important. Given that all 3 of the previous RCTs demonstrated reductions in median MV duration of at least 2.4 days, we considered this to be a plausible difference. In the SLEAP Pilot Trial, the median duration of MV for 65 patients was 7.5 days. In 2004-2005, the median duration of MV (or time to extubation) in 685 patients ventilated >2 days in 3 Toronto ICUs (Mount Sinai Hospital, University Health Network General and Western sites) was 7 days (IQR 3, 14) . Five exclusion criteria used in the SLEAP Pilot Trial were removed (known alcohol/sedative/analgesic abuse; psychiatric illness; any condition for which 6-month mortality is estimated to be >50%; nonEnglish speaking; sedative infusion for >24 hrs) to ensure that SLEAP patients in the main trial were more similar to a general medical-surgical ICU population. For SLEAP, we estimated a baseline time-to-extubation of 7 days. To compare the 2 time-toextubation distributions, a non-parametric Peto log-rank test was used for the primary analysis. To detect a 2 day reduction in time to extubation (Hazard Ratio of 1.4) with a power of 90%, a 2-sided alpha of 0.05, and a 10% non-compliance factor, a sample size of 205 patients per group (total 410) was needed. eFigure 1. Protocol for nursing management of analgesia and sedation during mechanical ventilation for patients in the protocolized sedation group, who were receiving fentanyl. Separate protocols were provided for patients receiving morphine or hydromorphone. Opioid and benzodiazepine infusions were initiated using the first page of the protocol; and managed thereafter using the second page of the protocol. Midaz= midazolam, loraz=lorazepam; midazolam or lorazepam could be administered within the protocol. Reassess SAS score in 1-2 hr & repeat above dosage assessment Notify MD if patient requires a change of greater than 10 mg/hr midaz/loraz or 100 mcg/hr fentanyl over 6-12 hr 7 DANGEROUS AGITATION Pulls at ETT, tries to remove catheters, climbs over bed rails, strikes at staff, thrashes side-to-side. 6 VERY AGITATED Does not calm, despite frequent verbal reminders; requires verbal reminding of limits, physical restraints; bites ETT.
Initiation of Sedation & Analgesia

AGITATED
Anxious or mildly agitated, attempts to sit up, calms down to verbal instructions.
CALM & COOPERATIVE
Calm, awakens easily, follow commands.
SEDATED
Difficult to arouse, awakens to verbal stimuli or gentle shaking but drifts off again, follows simple commands.
VERY SEDATED
Arouses to physical stimuli but does not communicate or follow commands, may move spontaneously.
eFigure 2. Protocol for nursing management of analgesia and sedation during mechanical ventilation for patients in the daily interruption group, who were receiving receiving morphine. Separate protocols were provided for patients receiving fentanyl or hydromorphone. Opioid and benzodiazepine infusions were initiated using the first page of the protocol; and managed thereafter using the second page of the protocol. Midaz=midazolam, loraz=lorazepam; midazolam or lorazepam could be administered within the protocol. 
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Surgical/Trauma subgroup
In the small pre-specified surgical/trauma subgroup, daily interruption was unexpectedly associated with shorter time to extubation. This subgroup fulfilled the following credibility criteria: the variable was a baseline characteristic, the hypothesis was specified a priori, the subgroup analysis was one of three hypotheses tested, and the effect was suggested by a within-study comparison 3 . However, the observed subgroup effect was inconsistent with our prespecified direction, the subgroup was small (N=68), and there were baseline imbalances. Given these reservations, we are unable to make any firm conclusions regarding the use of daily interruption in surgical patients, and further large trials in this population are necessary. The tables below show baseline characteristics (eTable 6), patient outcomes (eTable 7), and benzodiazepine and opioid administration (eTable 7) in the surgical/trauma patients, by group. 
